Dagdag na 10% tax sa soft drinks, carbonated at sweetened drinks, pinag-aaralan na ng Kongreso

admin   •   August 19, 2014   •   12887

Ang pagpapataw ng dagdag na 10% buwis sa mga inuming may matataas na sugar contents tulad ng mga soft drink ay pinag-aaralan na sa mababang kapulungan ng kongreso (UNTV News)

MANILA, Philippines — Pinag-aaralan na sa mababang kapulungan ng Kongreso ang pagpapataw ng dagdag na 10-porsiyentong buwis sa mga inuming may matataas na sugar contents tulad ng soft drinks, carbonated at sweetened drinks.

Ayon sa pagaaral, isang Pilipino ang namamatay kada isang segundo dahil sa mga komplikasyong dulot ng diabetes.

Sa pinakahuling tala ng World Health Organization (WHO), noong 2008 ay umabot na sa 3.5 milyong Pilipino ang may diabetes o isa sa kada limang Pilipino at posible pa itong lumobo sa 7.8 million sa taong 2030.

Sa House Bill No. 3365 na inihain ni Nueva Ecija Representative Estrellita Suansing, sinabi nito na isa sa pangunahing dahilan ng pagkakaroon ng iba’t ibang sakit gaya ng diabetes at obesity ay ang sobrang pag-inom ng soft drinks.

“We are not prohibiting the soft drinks here, we are just curving the consumption reducing the consumption because of the effect to the health,” paliwanag ng kongresista.

Batay sa pag-aaral ng University of the Philippines School of Economics, ang kalahating litro ng soft drinks ay katumbas ng 150-300 liters of water upang maalis ang mga toxic na dala nito sa katawan ng tao.

Ayon kay Suansing, sa pagpapataw ng 10-porsiyentong dagdag buwis sa soft drinks, carbonated at sweetened drinks ay bababa ng 8% ang consumption nito lalo na sa mga bata.

“No nutritional value to any of these drinks so as far as children is concern if we keep soft drinks, fruit juices, artificial drinks cheap children will have preference drinking these unhealthy beverages,” pahayag ni Dr. Cielo Magno, UP School of Economics.

Sa pagtaya naman ng Department of Finance, posibleng makakolekta ang bansa ng P10.77 bilyon kung maisasabatas ang panukalang dagdag buwis sa mga soft drink.

“This is based on the existing 2013 revenues of the large tax payers,” saad ni Finance Assistant Secretary Solidad Cruz.

Tumutol naman sa panukalang ito ang Beverage Industry Association of the Philippines (BIAP).

Ayon kay Atty. Adel Tamano ng BIAP, wala pang malinaw na pag-aaral sa relasyon ng pagpapataw ng dagdag na buwis sa pagpapababa sa kaso ng iba’t ibang uri ng sakit sa bansa.

Dagdag pa nito, posibleng magdulot pa ito ng negatibong epekto sa ekonomiya ng bansa.

Aniya, “Taxation is the wrong policy to address obesity and related health issues.”

Ayon sa author ng panukalang batas, sakaling maisabatas, ang lahat ng kikitain dito ay direktang mapupunta sa mga Pilipinong maaapektuhan ng kalamidad.

Sa susunod na pagdinig ng House Committee on Ways and Means ay ipatatawag nito ang mga kumpanyang nagbebenta ng mga nasabing produkto. (Grace Casin / Ruth Navales, UNTV News)

Over 193,000 doses of Pfizer COVID-19 vaccine arrive in Philippines

Robie de Guzman   •   May 11, 2021

MANILA, Philippines – The first batch of COVID-19 vaccines developed by Pfizer-BioNTech has been delivered in the Philippines.

The shipment arrived at the Ninoy Aquino International Airport (NAIA) Terminal 2 around 9 p.m. on Monday.

The initial batch of 193,050 doses of Pfizer vaccines was courtesy of the World Health Organization (WHO)-led COVAX Facility.

Vaccine czar Carlito Galvez Jr. earlier said the first shipment of Pfizer vaccines will serve as a logistical run to prepare for the arrival of additional Pfizer vaccine doses, which require storage temperature conditions of -70 degrees Celsius.

The Department of Health said this batch of Pfizer vaccines would be distributed to Metro Manila, Cebu, and Davao, which have facilities capable of handling the product to avoid wastage.

These will be used on priority groups A1 (health workers), A2 (senior citizens), and A3 (persons with co-morbidities).

The government hopes to get 1.3 million more Pfizer vaccines through the COVAX facility this May.

Pfizer-BioNTech is the fourth brand of vaccine against coronavirus disease that the Philippines received since the government rolled out its immunization program on March 1. Vaccine supplies from Sinovac, AstraZeneca and Gamaleya Institute have been delivered in the past weeks.

WHO approves Sinopharm COVID-19 vaccine for emergency use

Robie de Guzman   •   May 10, 2021

China’s Sinopharm COVID-19 vaccine will now be rolled out globally after it was approved for emergency use listing (EUL), the World Health Organization (WHO) said.

In an announcement, WHO director general Tedros Adhanom Ghebreyesus said the EUL granted for Sinopharm COVID-19 vaccine will expand the list of vaccines that the COVAX facility can provide to poor countries in need of vaccine supply.

“This expands the list of COVID-19 vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine,” Tedros said in a briefing on May 7.

WHO’s emergency use listing is a prerequisite for COVAX Facility vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products said in a separate statement.

The WHO said the EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements.

The assessment is performed by the product evaluation group, composed by regulatory experts from around the world and a Technical Advisory Group (TAG), in charge of performing the risk-benefit assessment for an independent recommendation on whether a vaccine can be listed for emergency use and, if so, under which conditions, it added.

In the case of the Sinopharm vaccine, the WHO assessment included on-site inspections of the production facility, the health body said.

The Sinopharm product is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell). Its easy storage requirements make it highly suitable for low-resource settings. It is the also first vaccine that will carry a vaccine vial monitor, a small sticker on the vaccine vials that change color as the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.

This is the first vaccine developed by a non-Western country to receive WHO backing. It is also the first time the WHO has given emergency use approval to a Chinese-made vaccine for any infectious disease.

The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a unit of Sinopharm subsidiary China National Biotec Group.

Following the approval, the WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks.

On the basis of all available evidence, the WHO said the vaccine efficacy for symptomatic and hospitalized disease was estimated to be 79%, all age groups combined.

The WHO, however, noted that only few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group.

“Nevertheless, WHO is not recommending an upper age limit for the vaccine because preliminary data and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons,” it said.

“There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations.  WHO therefore recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring to make the recommendation more robust,” it added.

Other COVID-19 vaccines included in WHO emergency use listing are those produced by Pfizer/BioNTech, AstraZeneca, Janssen (Johnson& Johnson) and Moderna.

DOH to file EUA application for Sinopharm COVID-19 vax

Robie de Guzman   •   May 10, 2021

MANILA, Philippines – The Department of Health (DOH) is set to file an emergency use authorization application for the COVID-19 vaccine manufactured by China’s state-owned drug firm Sinopharm.


In an interview, Health Secretary Francisco Duque III said the EUA application will be filed after the World Health Organization (WHO) approved the Sinopharm vaccine for emergency use.


This is the first vaccine developed by a non-Western country to receive WHO backing. It is also the first time the WHO has given emergency use approval to a Chinese-made vaccine for any infectious disease.

A WHO emergency listing means that a product is safe and effective and will also allow it to be included in COVAX facility – a global program that seeks to provide vaccine supply mainly for poor countries.


The DOH, however, stressed that the vaccine will still undergo thorough evaluation and strict regulatory process by the Food and Drug Administration even if it has been included in WHO emergency listing.


The Philippine Broadcast Hub

UNTV, 915 Barangay Philam,

EDSA, Quezon City M.M. 1104

(+632) 8396-8688 (Tel)

info@untv-newsandrescue.com (General inquiries)


UNTV is a major TV broadcast network with 24-hour programming. An Ultra High Frequency station with strong brand content that appeal to everyone, UNTV is one of the most trusted and successful Philippine networks that guarantees wholesome and quality viewing experience.